Non-Hodgkin Lymphoma

John M. Pagel, MD, PhD, discusses the evolution of treatment in diffuse large B-cell lymphoma.

Brad S. Kahl, MD, discusses the current treatment landscape in ​relapsed/refractory indolent non-Hodgkin lymphoma.

Kami J. Maddocks, MD, discusses the tolerability and promise of tafasitamab in combination with lenalidomide in relapsed or refractory DLBCL.

Kami J. Maddocks, MD, discusses the role of tazemetostat in patients with EZH2-mutant follicular lymphoma.

Shuo Ma, MD, PhD, discusses the evolving role of BTK inhibitors in B-cell malignancies, ongoing research efforts examining their use, safety concerns to be aware of with the agents, and next steps for research.

Lori A. Leslie, MD, highlights ibrutinib, acalabrutinib, and zanubrutinib, the 3 FDA approved BTK inhibitors that have become very important weapons in the treatment arsenal for B-cell malignancies.

The European Commission has approved an expanded indication of ibrutinib for use in combination with rituximab in treatment-naïve adult patients with chronic lymphocytic leukemia.

Monica Balzarotti, MD, discusses the current treatment landscape of DLBCL, including the recent FDA approval of selinexor for the treatment of adult patients with relapsed/refractory disease.

Joshua Brody, MD, discusses recent developments in DLBCL treatment, the role of selinexor, and the need for effective biomarkers of response in the space.

A supplemental biologics license application has been filed with the FDA for axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma following 2 or more previous lines of systemic therapy.

Caron Jacobson, MD, discusses the high-risk patient population within relapsed/refractory indolent non-Hodgkin lymphoma included in the phase 2 ZUMA-5 study.

Kami J. Maddocks, MD, discusses emerging therapies in follicular lymphoma.

Brian T. Hill, MD, PhD, sheds light on XPO1 as a target in diffuse large B-cell lymphoma, the emergence of selinexor in the treatment landscape, and exciting agents in the pipeline.

Lori A. Leslie discusses several key studies evaluating emerging approaches in the relapsed/refractory follicular lymphoma paradigm.

Pashna N. Munshi, MD, discusses the CAR T-cell therapies that have emerged in the lymphoma space and highlights the next steps for research with these products.

Investigators are evaluating the efficacy of enzastaurin, a PCKß inhibitor, in combination with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with high-risk DGM1–positive diffuse large B-cell lymphoma.

Lori A. Leslie, MD, lymphoma attending, discusses frontline treatment options in follicular lymphoma.

Tafasitamab has been added to the Clinical Practice Guidelines in Oncology by the National Comprehensive Cancer Network for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplant.

The novel phospholipid-drug conjugate CLR 131 induced a 100% overall response rate in patients with relapsed/refractory lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.

Nilanjan Ghosh, MD, PhD, compares different BTK inhibitors in B-cell malignancies.

Manfred Welslau, MD, discusses​ the potential benefits of ​using biosimilars in diffuse large B-cell lymphoma.

The FDA has granted a priority review designation to a new drug application for umbralisib for the treatment of patients with previously treated marginal zone lymphoma who have received at least 1 prior anti-CD20–based treatment.

Manfred Welslau, MD, discusses findings from the REFLECT interim analysis that reconfirmed the activity of the rituximab biosimilar SDZ-RTX, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with diffuse large B-cell lymphoma.